The Eleventh Eilat Conference on New Antiepileptic Drugs (AEDs)-EILAT XI, took place in Eilat, Israel from the 6th to 10th of May 2012. About 100 basic scientists, clinical pharmacologists and neurologists from 20 countries attended the conference, whose main themes included ''Indications overlapping with epilepsy'' and ''Securing the successful development of an investigational antiepileptic drug in the current environment''. Consistent with previous formats of this conference, a large part of the program was devoted to a review of AEDs in development, as well as updates on AEDs introduced since 1994. Like the EILAT X report, the current manuscript focuses only on the preclinical and clinical pharmacology of AEDs that are currently in development. These include brivaracetam, 2-deoxy-glucose, ganaxolone, ICA-105665, imepitoin, NAX 801-2, perampanel and other AMPA receptor antagonists, tonabersat, valnoctamide and its homologue sec-propylbutylacetamide (SPD), VX-765 and YK3089. Since the previous Eilat conference, retigabine (ezogabine) has been marketed and four newer AEDs in development (NAX 810-2, SPD, tonabersat and VX-765) are included in this manuscript.
Introduction and rationale for development
Brivaracetam (UCB 34714) is a novel high-affinity synaptic vesicle protein 2A (SV2A) ligand (Kenda et al., 2004; Lynch et al., 2004) . Brivaracetam also displays inhibitory activity at neuronal voltage-dependent sodium channels (Niespodziany et al., 2009; Zona et al., 2010) . Brivaracetam is currently in Phase III development for epilepsy.
Pharmacology
The preclinical activity profile of brivaracetam in a wide range of animal models of focal and generalized seizures and epilepsy (Table 1) suggests potential broad spectrum activity with a potency and efficacy superior to levetiracetam. Data suggest that brivaracetam has anticonvulsant and disease-modifying effects against refractory self-sustaining status epilepticus in rats, and that brivaracetam is effective at lower doses when combined with low-dose diazepam (Wasterlain et al., 2009 ). The preclinical profile of brivaracetam has been summarized previously . Doses of brivaracetam that exert anticonvulsant effects in amygdala-kindled rats were devoid of negative impact on learning and memory performance in normal and amygdalakindled rats evaluated in the Morris water maze (Detrait et al., 2010) . Furthermore, brivaracetam did not affect long-term potentiation in hippocampal slices. These findings suggest that brivaracetam would not be expected to have detrimental effects on hippocampal-dependent cognitive function in patients with epilepsy.
A strong functional correlation between in vitro SV2A binding affinity and anticonvulsant potency in animal models of both focal and generalized epilepsy has been established (Kaminski et al., 2008) . Consistent with these findings, ex vivo binding studies demonstrated that the time-and dose-dependency of brivaracetam binding to brain SV2A was correlated with seizure protection in audiogenic mice (Gillard et al., 2011) . Brivaracetam was more potent and faster than levetiracetam in achieving maximal SV2A occupancy and seizure protection.
Simulations based on in vitro and ex vivo binding experiments in mice predicted that, at 50 mg/day, brivaracetam should occupy more than 80% of SV2A in patients with epilepsy (Gillard et al., 2011) . Similarly, human brain concentrations of brivaracetam predicted using physiological models, combined with mouse ex vivo binding pharmacokinetic/pharmacodynamic modeling, estimated that brivaracetam 50 mg/day would occupy approximately 50% of SV2A in human brain (Brochot et al., 2010) .
Toxicology
Brivaracetam demonstrated low acute oral toxicity in mice, rats, and dogs. Toxicology data have been summarized previously .
Clinical pharmacokinetics
Brivaracetam is well absorbed from the gastrointestinal tract and shows linear pharmacokinetics following single oral doses up to 600 mg (Sargentini-Maier et al., 2007; von Rosenstiel and Perucca, 2009 ). The extent of binding to plasma proteins is small (≤20%) (Sargentini-Maier et al., 2008a) and the volume of distribution is in the order of 0.6 L/kg (Rolan et al., 2008) . The half-life of brivaracetam is about 8 h (Rolan et al., 2008; Sargentini-Maier et al., 2007) .
Brivaracetam is eliminated primarily by biotransformation through hydrolysis of the acetamide group and CYP2C19-mediated hydroxylation (Sargentini-Maier et al., 2008a; von Rosenstiel and Perucca, 2009 ). The metabolites are pharmacologically inactive and do not accumulate in plasma to any significant extent (von Rosenstiel and Perucca, 2009; Sargentini-Maier et al., 2008a) . After administration of a radiolabelled dose of brivaracetam, over 95% of the radioactivity is recovered in urine within 72 h, of which less than 10% is represented by unchanged drug (Rolan et al., 2008; Sargentini-Maier et al., 2008a) . The CYP2C19 genetic polymorphism has only a modest influence on brivaracetam pharmacokinetics, with a 30% decrease in clearance of brivaracetam being reported in subjects with inactive *2 or *3 mutations (Stockis et al., 2011) . As a result, no dose adjustments are considered necessary in subjects bearing CYP2C19 mutations .
In population pharmacokinetic studies using data from patients included in Phase II and III trials, plasma brivaracetam levels were not found to be significantly affected by gender, age, race, dose, renal function (creatinine clearance), and concomitant AEDs, except for enzyme inducing AEDs which were associated with increased brivaracetam clearance . The pharmacokinetic profile of brivaracetam in the elderly (Sargentini-Maier et al., 2008b) and in subjects with severe renal impairment not requiring dialysis (creatinine clearance < 15 mL/min, n = 6; 15-29 mL/min, n = 3) (Sargentini-Maier et al., 2012) did not differ to a major extent from those found in non-elderly healthy subjects. In subjects with severe hepatic impairment (Child-Pugh Class C), exposure to brivaracetam is increased by up to 50-60% compared with healtly control subjects .
Drug interactions
In adjunctive-therapy trials in patients with epilepsy, brivaracetam treatment was found not to cause significant changes in the plasma concentrations of carbamazepine, lamotrigine, levetiracetam, monohydroxycarbazepine (licarbazepine), phenobarbital, phenytoin, topiramate, valproic acid, or zonisamide. The concentrations of the 10,11-epoxide metabolite of carbamazepine were increased at brivaracetam doses of ≥50 mg/day, and at doses of 100-150 mg/day it approached a concentration of 3.0 g/mL, which is close to the upper limit of the range found in subjects not receiving brivaracetam. These data suggest that monitoring for potential carbamazepineassociated adverse effects is indicated when brivaracetam is added on to the therapeutic regimen of patients stabilized on high doses of carbamazepine .
At a dose of 100 mg/day, brivaracetam did not modify the pharmacokinetics of the components of an oral contraceptive steroid (30 g ethinylestradiol and 150 g levonorgestrel) (Stockis et al., 2009 ). In the same study, the oral contraceptive did not affect trough brivaracetam concentrations.
Efficacy data
Phase IIb studies Two randomized, double-blind, placebo-controlled adjunctive-therapy Phase IIB studies were completed in patients (16-65 years old) with partial-onset seizures (POS) uncontrolled despite treatment with up to 2 concomitant AEDs. In study N01193 (NCT00175825), which assessed brivaracetam doses of 5, 20, and 50 mg/day, the percent reduction over placebo in baseline-adjusted POS frequency (primary efficacy endpoint) achieved statistical significance for the 50 mg/day dose (p = 0.004) . Secondary efficacy analysis (≥50% responder rate and median percent reduction from baseline in POS frequency/week) provided supportive evidence for the efficacy of brivaracetam 20 mg/day. In Study N01114 (NCT00175929), which assessed brivaracetam doses of 50 and 150 mg/day, no statistically significant difference between brivaracetam and placebo was found for the primary efficacy endpoint (Van Paesschen et al., 2007) . However, a clear differentiation from placebo was found on several secondary efficacy endpoints for both brivaracetam doses.
Phase III fixed-dose studies Two randomized, double-blind, placebo-controlled adjunctive-therapy Phase III trials were conducted in adults (16-70 years old) with refractory POS receiving up to 2 concomitant AEDs. In both trials, brivaracetam was administered b.i.d. for 12 weeks without titration and the primary efficacy endpoint was percent reduction over placebo in baseline-adjusted POS frequency. Statistical comparisons were conducted in a pre-defined order starting with 50 mg/day for both studies.
In study N01253 [NCT00464269], which assessed doses of 5, 20 and 50 mg/day in a total of 400 randomized patients, statistical significance versus placebo (p = 0.02) was reached for the primary efficacy endpoint for the 50 mg/day dose, but not for the lower doses . In study N01252 [NCT00490035], which investigated doses of 20, 50 and 100 mg/day in 399 patients, statistical significance versus placebo on the primary efficacy endpoint (p = 0.261) was not achieved for the predefined initial comparison at 50 mg/day . Statistical significance, however, was achieved for 100 mg/day at the nominal 0.05 significance level, a finding which was supported by the secondary efficacy analyses (≥50% responder rate and median percent POS frequency reduction) at the 100 mg/day dose .
Phase III flexible-dose study A prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-dose trial (N01254 [NCT00504881]) was conducted in adults (16-70 years) with uncontrolled POS or generalized seizures despite treatment with 1-3 concomitant AEDs (Kwan et al., 2010) . Brivaracetam was initiated at 20 mg/day and increased stepwise to a maximum of 150 mg/day at the investigator's discretion. Four hundred and eighty patients were randomized (359 brivaracetam, 121 placebo); 431 (89.8%) with POS and 49 (10.2%) with primary generalized seizures. During the 16-week treatment period, median percent reduction from baseline in POS frequency/week was 26.9% for brivaracetam versus 18.9% for placebo (p = 0.070); 50% responder rates were 30.3% for brivaracetam versus 16.7% for placebo (p = 0.006). Preliminary data suggest potential efficacy of adjunctive brivaracetam in adults with generalized epilepsy. Of the 49 patients with primary generalized seizures, 34/36 (94.4%) who received brivaracetam and 13/13 (100%) who received placebo completed the 16-week treatment period (Kwan et al., 2010) . Seizure types experienced during the baseline period were tonic-clonic (21 brivaracetam, 8 placebo), absence (12 brivaracetam, 6 placebo), tonic (6 brivaracetam, 1 placebo), myoclonic (5 brivaracetam, 0 placebo), clonic (1 brivaracetam, 2 placebo) and atonic (1 brivaracetam, 1 placebo). Median baseline generalized seizure days/week was similar in both groups (brivaracetam 1.42; placebo 1.47). Exploratory efficacy analysis showed that during the treatment period the median generalized seizure days/week decreased to 0.63 on brivaracetam and remained relatively stable on placebo (1.26). Median percentage reductions from baseline and ≥50% responder rates in generalized seizure days/week were higher on brivaracetam (42.6% and 44.4%, respectively) compared with placebo (20.7% and 15.4%, respectively). Three (8.3%) patients on brivaracetam were seizure-free during the entire treatment period compared with none on placebo.
Tolerability and adverse event profile
In all studies conducted to date, brivaracetam (5-150 mg/day) showed a favourable safety and tolerability profile Biton et al., 2009 ). In the two Phase III fixed-dose studies, a similar proportion of patients on brivaracetam (range: 56.6-79.0%) reported at least one treatment-emergent adverse event (TEAE) compared with placebo (range: 53.0-70.4%). In all treatment arms, the proportion of completers was high (range: 84.5-94.0% for brivaracetam versus 92.0-94.9% for placebo) and few patients discontinued treatment due to TEAEs (range: 4.0-8.2%, for brivaracetam versus 2.0-4.0% for placebo). These favourable safety and tolerability results were confirmed by the Phase III flexible-dose trial, in which a similar proportion of brivaracetam and placebo patients reported at least one TEAE (66.0% vs 65.3%) (UCB, data on file). Completion rates were 90% for brivaracetam and 91.7% for placebo, and discontinuation rates for TEAEs were 6.4% for brivaracetam and 5.8% for placebo (Kwan et al., 2009) . The majority of TEAEs reported in the Phase III trials were mild to moderate. Those reported most frequently were headache (range: brivaracetam 6.0-18.2%, placebo 9.0-19.8%), somnolence (range: brivaracetam 6.1-16.8%, placebo 4.1-7.1%), dizziness (range: brivaracetam 5.0-15.8%, placebo 5.0-9.2%), and fatigue (range: brivaracetam 3.0-13.0%, placebo 2.0-4.1%) Kwan et al., 2009) .
In a well controlled QT safety study in healthy subjects, brivaracetam (75 and 400 mg b.i.d.) was found not to affect cardiac repolarization (Rosillon et al., 2008) .
Ongoing clinical studies
A Phase III, randomized, double-blind, placebo-controlled, fixed-dose study (N01358, NCT01261325) in adults with POS inadequately controlled with 1-2 concomitant AEDs has been initiated to evaluate the efficacy and safety of brivaracetam 100 and 200 mg/day as adjunctive treatment.
Three Phase III, open-label, multicenter, flexible-dose (up to a maximum dose of 150 mg/day) long-term followup trials (N01125, NCT00175916; N01199, NCT00150800; N01315, NCT00761774) are ongoing to evaluate the longterm safety/tolerability and maintenance of efficacy of brivaracetam in patients with epilepsy who had participated in previous trials.
A multicenter, open-label, adjunctive-therapy randomized trial (N01258, NCT01405508) is ongoing to investigate the safety and tolerability of brivaracetam 200 mg/day administered intravenously as an infusion or bolus in adults with POS or generalized seizures.
A multicenter, open-label trial (N01263, NCT00422422) is ongoing to evaluate the steady state pharmacokinetics, safety, and preliminary efficacy of adjunctive brivaracetam in children with any type of epilepsy aged from at least 1 month to 16 years. The dose of brivaracetam is adjusted by body weight to achieve similar exposure to adults at doses of 50-200 mg/day.
Introduction
2-Deoxy-D-glucose is a glucose analogue and glycolytic inhibitor. The anticonvulsant and disease-modifying antiepileptic properties of 2-deoxy-D-glucose were defined in animal models during investigations aimed at elucidating the mechanisms underlying the efficacy of the ketogenic diet. 2-Deoxy-D-glucose is currently in preclinical development for the treatment of epilepsy. More detailed information on this compound can be found in the reports of previous Eilat conferences .
Pharmacology
Glycolytic inhibition by 2-deoxy-D-glucose 2-Deoxy-D-glucose undergoes activity-dependent uptake into cells through glucose transporters. It then undergoes phosphorylation to 2-deoxy-D-glucose-6-phosphate, which cannot undergo isomerization to fructose-6-phosphate, thereby preventing subsequent steps of glycolysis.
Anticonvulsant profile in experimental models
2-Deoxy-D-glucose displays both acute and chronic mechanisms of action in experimental in vivo models. In the mouse in vivo 6 Hz model, 2-deoxy-D-glucose acutely protected against seizures evoked by 6 Hz 22 mA corneal stimulation at doses of 75-300 mg/kg i.p. with an ED 50 of 79.7 mg/kg (Table 1) . The time to peak action was 15 min at a dose of 75 mg/kg i.p. and 1 h at a dose of 100 mg/kg i.p. 2-Deoxy-D-glucose protected against audiogenic seizures evoked in Frings mice 2 h after administration of 220-250 mg/kg i.p. The ED 50 was 206.4 mg/kg, and the time to peak effect was 2 h at these doses. 2-Deoxy-D-glucose also demonstrated evidence of anticonvulsant activity against seizures evoked by pentylentetrazol at 30 min after administration at doses of 200-400 mg/kg i.p. and 50-400 mg/kg per os (p.o.), but overall the results were not sufficient to calculate an ED 50 or a time to peak effect. There was no protective effect of 2-Deoxy-D-glucose against MES in rats when tested 15 min to 4 h after administration of 100-200 mg/kg p.o. (Stafstrom et al., 2009 ).
2-Deoxy-D-glucose displays in vivo chronic ''diseasemodifying'' antiepileptic effects consisting of 2-fold slowing of progression of repeated seizures evoked by perforant path or olfactory bulb kindling (Garriga-Canut et al., 2006; Stafstrom et al., 2009 ). These effects have been observed at doses of 37.5-50 mg/kg administered 30 min prior to perforant path stimulation. In addition, effects on disease progression have been observed when 2-Deoxy-D-glucose was administered immediately after, and approximately 10 min after, evoked seizures (Sutula and Franzoso, 2008) . This novel ''post-seizure'' action is most likely based on enhanced activity-dependent uptake of 2-Deoxy-D-glucose into those brain regions with increased energy demand; e.g., hyperactive neural circuits as occurs during seizures. This novel action of 2-Deoxy-D-glucose represents a potential opportunity for ''post-seizure'' anticonvulsant administration for the treatment of seizure clusters and status epilepticus. 2-Deoxy-D-glucose also reduces the latency to seizures evoked by pilocarpine and kainic acid (Lian et al., 2007) .
Neuroprotective action in experimental traumatic brain injury (TBI)
2-Deoxy-D-glucose displays neuroprotective effects against the progressive structural damage in the frontal cortex or dorsal hippocampus after TBI induced by controlled cortical impact (CCI) model using Sprague Dawley rats. 2-Deoxy-D-glucose also displays neuroprotective effects following TBI in unique strains of rats bred for their susceptibility or resistance to kindling progression evoked by perforant path stimulation of the hippocampus (Hutchinson et al., 2010) . After CCI, serial in vivo magnetic resonance imaging (MRI) and diffusion tensor imaging (DTI) performed over a 6 month period demonstrate progresively increasing ventricle volume, increasing hippocampal diffusion abnormalities, and evolving patterns of hippocampal and corpus callosum anisotropy. Brief treatment with 2-Deoxy-D-glucose (40 mg/kg at the time of injury and 250 mg/kg/day for 2 weeks) did not modify the severity of the initial injury.
However, this treatment with 2-Deoxy-D-glucose did reduce the progression of the observed structural damage that was assessed by MRI and DTI measures over the 6 month post-TBI observation period. Distinct patterns of structural abnormalities were observed in kindling-susceptible and kindling-resistant rat strains. Studies are underway to evaluate the possibility that treatment with 2-Deoxy-D-glucose might also have favorable effects on long-term consequences such as post-traumatic epilepsy and post-traumatic stress disorder.
Toxicology
Cardiac toxicity and increased incidence of pheochromocytomas were reported with chronic administration of 2-deoxy-D-glucose at doses of 0.25-0.4% of dietary intake (corresponding to total daily exposures of ∼125-200 mg/kg/day). Reduced life-span was also reported at a daily dietary intake of 0.4% (Minor et al., 2010) . Cardiotoxicity was accompanied by myofibrillar vesicular alterations consistent with autophagy, and subtle evidence of myofibrillar vesicular alterations was also reported at dietary exposures of about 20-25 mg/kg/day. As discussed in more detail in a previous report , the reversibility and significance of these observations are currently under investigation.
Experiments in rodents using the Morris water maze test found no effects on spatial memory at doses nearly 30 times greater than the minimum dose required to reduce kindling progression . Further, no effects on spatial memory at 15 min after treatment with 50 or 250 mg/kg, i.p. were observed. Dose-dependent effects in the open field tests were reported at doses of 250 mg/kg i.p., but not at doses of 50 mg/kg i.p. (Stafstrom et al., 2007; Ockuly et al., 2012) .
Pharmacokinetics and cerebral uptake mechanisms
Intravenous 2-Deoxy-D-glucose (40 mg/kg) in normal human volunteers induces regional increases in cerebral blood flow in cingulate gyrus, sensorimotor cortex, superior temporal cortex, occipital cortex, basal ganglia, limbic system, and hypothalamus (Elman et al., 1999) , which are likely to explain the shorter latencies of onset of behavioral seizures in response to intravenous administration of convulsants reported in some rodent studies (Gasior et al., 2010) . In Phase I studies in human cancer patients, the half-life of of 2-Deoxy-D-glucose during 14 days of once daily oral dosing at 45 mg/kg was 7.3-8.2 h (Stein et al., 2010) .
Tolerability and safety in clinical studies
2-Deoxy-D-glucose has been evaluated in Phase I/II cancer trials and reported to be well tolerated in dose escalation studies up to 64 mg/kg/day for 5 to 8 weeks (Raez et al., 2007 , Singh et al., 2005 . In a recent open label multiple dose Phase I study in patients with prostate cancer, doselimiting reversible toxicity of grade 3 asymptomatic QTc prolongation was seen in two patients treated at a dose of 60 mg/kg, but no evidence of QTc prolongation was observed at doses of 45 mg/kg (Stein et al., 2010) .
Planned studies
Further preclinical toxicology and pharmacokinetic studies are planned. Planned clinical studies include, in addition to conventional trial designs in a variety of seizure types, protocols for administration during seizure clusters as well as status epilepticus 
Pharmacology
Neurosteroids including ganaxolone have two separate effects on GABA A receptors: at low concentrations they potentiate the action of GABA and at higher concentrations directly activate the receptor; these actions occur at two distinct sites on the receptor complex that do not correspond with the modulatory sites of benzodiazepines and barbiturates (Hosie et al., 2006) . Unlike benzodiazepines that are specific for synaptic GABA A receptors, neurosteroids modulate both synaptic and extrasynaptic GABA A receptors and their modulatory action is of greater magnitude for extrasynaptic GABA A receptor isoforms that contain a ␦ subunit (Herd et al., 2007) . These isoforms have decreased expression in rodent models of temporal lobe epilepsy (Joshi et al., 2011) . Ganaxolone has anticonvulsant and protective activity in diverse rodent seizure models, including clonic seizures induced by the chemoconvulsants pentylenetetrazol, bicuculline, flurothyl, tert-butylbicycloorthobenzoate, aminophylline; limbic seizures in the 6 Hz model; amygdala and cocaine-kindled seizures; and corneal kindled seizures (see Rogwski, 2012) . In female amygdala kindled mice, ganaxolone produced a dose-dependent suppression of behavioral and electrographic seizures (Reddy and Rogawski, 2010) . In chronically treated rats, tolerance does not occur to the anticonvulsant activity of ganaxolone (Reddy and Rogawski, 2000) .
Toxicology and safety pharmacology
There was little evidence of target organ or systemic toxicity associated with either single-or multiple-dose treatment with ganaxolone (6 months in rat and 1 year in dog) (Marinus Pharmaceuticals, data on file). Hematologic or serum chemistry parameters were not altered, and no anatomic changes were observed. Ganaxolone was not teratogenic in rats and mice and did not significantly affect the development of offspring. Specifically, there were no effects on fertility or embryofetal development in rats at doses of 40 mg/kg/day, and there were no effects on peri-postnatal development except a slight decrease in body weight (up to 6%) at this dose. In a neonatal rat study at a dose of 50 mg/kg/day, no adverse effects were obtained. In mice, no effects on embryofetal development were demonstrated at a higher dose of 300 mg/kg/day. Ganaxolone also showed no potential for mutagenicity or carcinogenicity. In studies performed to assess central nervous system behavioral effects in mice, ganaxolone showed less of an interaction with ethanol than did valproic acid in the hanging wire-mesh test of ataxia and ganaxolone affected cognitive function in an animal passiveavoidance paradigm only at doses causing ataxia. Dosing in toxicology and safety studies was limited only by sedation and, in rodents, by liver weight gain associated with CYP induction.
Clinical pharmacokinetics
Ganaxolone is a lipophilic, high clearance compound. After administration of a single dose of ganaxolone, plasma levels rapidly decline due to metabolism and tissue distribution followed by a longer elimination phase. Multiple dosing with the ganaxolone capsule formulation achieved steady state within 48 h when ganaxolone was dosed 200, 400, or 600 mg b.i.d. with a standard meal or snack, and the effective half-life was 7-10 h. Mean peak plasma concentrations (C max ) and AUC (0) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) at steady-state were close to doseproportional (Marinus Pharmaceuticals, data on file; .
Because of its aqueous insolubility, formulationdependent food effects have been observed where absorption is higher in the fed than in the fasted state. To enhance its bioavailability, ganaxolone has been formulated in a nanosized particulate suspension and a nanosized particulate capsule. The capsule formulation at a 400 mg dose gave approximately 2-fold higher AUC and 3-fold higher Cmax levels in a high-fat fed state compared to the fasted state. Based on C max , AUC and trough levels at steady state, 400 to 600 mg b.i.d.dosing of the ganaxolone capsule formulation provides comparable ganaxolone exposure to 500 mg t.i.d. dosing of the suspension formulation (Marinus Pharmaceuticals, data on file; .
Drug interactions
Results of a midazolam interaction study (1042-0402) in normal volunteers with the capsule formulation of ganaxolone dosed 400 mg b.i.d. for 12 days indicated that ganaxolone is not a CYP3A4 inhibitor and showed low or no potential to induce CYP3A4 metabolism (<30% change in midazolam pharmacokinetic parameters comparing pre-ganaxolone dosing versus concomitant ganaxolone dosing at steady state). This result is consistent with in vitro studies showing that ganaxolone has low potential to affect the disposition of other drugs. However, data from the 1042-0600 study did show effects of concomitant administration of strong CYP3A4 inducers (carbamazepine and phenytoin) on ganaxolone pharmacokinetics (approximately 40% higher ganaxolone clearance than coadministration with other AEDs). In vitro studies have shown that the CYP3A4 inhibitor (ketoconazole) blocks the metabolism of ganaxolone (Marinus Pharmaceuticals, data on file).
Clinical efficacy
Prior to being acquired by the current sponsor, ganaxolone was studied in three open-label pediatric studies and a double-blind randomized pre-surgical study in adults and children with seizure disorders (Laxer et al., 2000; Kerrigan et al., 2000; Pieribone et al., 2007) . A double-blind randomized trial in infantile spasms (West Syndrome) under the current sponsor was reported previously .
The current sponsor has also completed a doubleblind, placebo-controlled study of ganaxolone (1042-0600) as adjunctive therapy in adults with POS, which was originally reported in the summary from Eilat X ; additional information from a follow-on open label extension study is reported here. In the double-blind study, adult subjects aged 18-69 years, with POS with or without secondary generalization refractory to conventional AEDs were randomized in a 2:1 ratio to receive ganaxolone (n = 98) or placebo (n = 47). Baseline seizure frequency per 28 days was 6.5 in the ganaxolone group and 9.2 in the placebo group. Mean duration of illness was 25 years, and 75% of the study population took 2 or 3 concomitant AED medications. After an 8-week baseline period, participants were titrated to 1500 mg/day (3 divided doses with a 300 nm nanosized ganaxolone suspension formulation) over a 1-2-week period and maintained at that dose for an additional 8 weeks. Downward dose adjustments were permitted if necessary because of tolerability.
In this double-blind study, ganaxolone treatment produced an 18% decrease in mean weekly seizure frequency, compared with a 2% increase for placebo over the 10-week treatment period (p = 0.014). Responder rates (proportions of subjects with greater than 50% reduction in seizures during the maintenance phase) were 26% for the ganaxolone group versus 13% for placebo (p = 0.057). Of 131 completers, 94% entered a 104-week open-label extension study.
The objective of the open-label extension was to evaluate the long-term safety, tolerability and efficacy of ganaxolone at a target dose of 1500 mg/day. Subjects were dosed for a mean of 274 days (39 weeks). Most subjects (89%) reached 1500 mg/day and 72% were maintained on this dose before tapering. Thirty-eight subjects (30%) completed more than 52 weeks of treatment before the study was terminated for administrative reasons.
Efficacy in the open-label extension study was reported as the median and mean change in weekly seizure frequency at endpoint compared to the baseline from the beginning of the double-blind study. For all subjects at endpoint, median and mean improvement in weekly seizure frequency were 23% and 14% respectively. Subjects previously randomized to ganaxolone (n = 79) in the double-blind study had median improvement in weekly seizure frequency of 14% at endpoint while those randomized to placebo had median weekly seizure frequency improvement of 35% (n = 41). Twenty-four percent of all subjects met responder criteria (50% improvement) at endpoint, 29% having originally been randomized to placebo and 22% having been randomized to ganaxolone.
Tolerability and safety in clinical studies
More than 900 adults and children have been exposed to ganaxolone in Phase I and Phase II studies. The drug was found to be generally safe and well-tolerated at the doses used (for Phase II studies, up to 1875 mg/day in adults and up to 54 mg/kg/day in infants). Tolerability and safety in children and infants has been described previously .
In the double-blind, randomized trial described above (study 1042-0600) in 147 adults, TEAEs reported by at least 5% of patients and at least twice as common in the ganaxolone group versus the placebo group were dizziness, fatigue (both 16% versus 8%) and somnolence (13% versus 2%). Seven percent of ganaxolone subjects and 6% of placebo subjects discontinued treatment due to TEAEs. There were no deaths during the study, and serious TEAEs occurred in 5% of ganaxolone versus 8% of placebo treated subjects. No clinically important trends were seen in clinical laboratory tests, electrocardiograms (ECGs), vital signs or body weight.
Ganaxolone continued to be safe and well tolerated in the open-label extension study. TEAEs reported in greater than 10% of subjects were headache (21%), convulsion (16%), fatigue (16%), fall (14%), nasopharyngitis (14%), dizziness (13%), contusion (12%), nasal congestion (10%). Serious TEAEs were reported in 14% of subjects, and 8% were not related to the underlying disease. Median weight change at endpoint was less than 0.5 kg. There were no trends of important changes in chemistry, hematology, vital signs, physical and neurological examinations, or ECGs. No new safety concerns were identified during extended treatment with ganaxolone for up to 104 weeks.
Conclusions and ongoing studies
Data from a 10-week, double-blind, placebo-controlled study of ganaxolone (1500 mg/day) as adjunctive therapy of adults with treatment-refractory POS as well as data from the 104-week open-label extension study show the drug to be efficacious, safe and well-tolerated. Importantly, there was no evidence of weight gain with extended exposure. The most recent clinical trial results in conjunction with several previous studies support development of ganaxolone for the adjunctive treatment of POS. Ganaxolone represents a new, mechanistically novel AED. The clinical information available indicates that the drug is safe in all infants, pediatrics and adults. Data from non-clinical studies suggest that ganaxolone may have low risk for use in pregnancy. Therefore, ganaxolone has the potential to provide important clinical benefit to subgroups of epilepsy patients who currently have limited treatment options.
Neurosteroids have also been proposed for study in a broad range of neurological and psychiatric conditions apart from epilepsy. Therapeutic utility may result from GABA A receptor modulation as well as effects on neuronal and glial differentiation, myelination, inflammation, and because of neuroprotective properties. Potential additional uses of ganaxolone are being explored through proof-of-concept studies in posttraumatic stress disorder and fragile X syndrome, which are currently in progress.
Introduction
ICA-105665 (PF-04895162) is a highly selective opener of neuronal Kv7 (KCNQ) potassium channels; the molecular components of the slow voltage-gated M current (Table 2) . Its chemical structure has not yet been disclosed. A more detailed description of the preclinical pharmacology and toxicology may be found in . Clinical data have previously been presented in abstract form at the American Epilepsy Society meetings in 2009 and 2010 Rigdon et al., 2009; Risner et al., 2009, and Biton et al., 2010) .
Pharmacology Anticonvulsant activity in animal models
In vivo, ICA-105665 protects against maximal electroshock (MES), scMetrazol, (scMet) 6 Hz and kindled seizures (Tables 1 and 3 ). In tests conducted by the sponsor, ED 50 s were ≤1 mg/kg for s.c. pentylentetrazol and MES. The compound did not affect the ability of rats to maintain position on a rotorod at doses up to the highest dose tested (i.e., 100 mg/kg po). ICA-105665 was also tested by the Anticonvulsant Screening Project of the National Institute of Neurological Disorders & Stroke (ASP-NINDS, NIH). In mice, ICA-105665 was active in the MES, s.c. pentylentetrazol, 6 Hz psychomotor seizures, and audiogenic seizure tests. ICA-105665 elevated seizure threshold in the i.v. pentylenetetrazol assay. In rats, ICA-105665 did not produce signs of toxicity by the minimal motor impairment test at p.o. doses up to 500 mg/kg. It protected against MES-induced tonic extension seizures and was active in the hippocampal kindled rat model of POS. ICA-105665 was also active in the lamotrigineresistant amygdala kindled rat model of pharmacoresistant epilepsy).
Mechanism of action
ICA-105665 opens cloned human neuronal Kv7 channels with EC50's of 0.3 M (Kv7.2/7.3), 1.5 M (Kv7.3/7.5) and 3.3 M (Kv7.4). ICA 105665 did not interact with a variety of other ion channels, including the cardiac ion channels.
Toxicology
Safety pharmacology, 6 month rodent and 9 month nonrodent toxicity, as well as reproduction toxicity and genotoxicity studies required to meet International Conference on Harmonization (ICH) guidelines have been completed. Common findings at the higher doses in rodents have included decreased body weight gain and food consumption. In rodents and non-human primates, common clinical signs at the higher doses have included tremors, ataxia and hypoactivity.
Clinical pharmacokinetics
In healthy volunteers, ICA-105665 was well-tolerated following single oral doses up to 400 mg and multiple doses up to 600 mg/day (300 mg b.i.d.). The compound is highly bound (>99%) to plasma proteins, primarily albumin. Mean half-life values after oral administration ranged from 5 to 9.5 h Pharmacokinetics were linear after single and repeated doses, with area under the plasma concentration-time curve (AUC) and C max values increasing approximately in proportion to dose. In 14 patients with epilepsy treated with 100 and 200 mg b.i.d. for 7 days, the mean half-life of ICA-105665 was similar to that found in healthy volunteers.
Drug interactions
Formal drug interaction studies have not been conducted. ICA-105665 at concentrations up to 30 M (highest concentration tested) did not inhibit CYP enzymes or P-glycoprotein mediated transport, and studies conducted using fresh human hepatocytes indicate it is unlikely to induce liver enzymes.
Early Phase II study
To establish that ICA-105665 penetrates the blood-brain barrier and engages neuronal Kv7 channels, its ability to reduce the photoparoxysmal EEG response was investigated in epilepsy patients with photosensitivity, using standardized methods (Kasteleijn-Nolst Trenité et al., 1996) . Cohorts of 4-6 subjects (100, 200, 400 and 500 mg single dose) were tested, with a single subject being tested at 600 mg (ClinicalTrials.gov identifier: NCT00979004). Subjects were exposed to photic stimulation (2-60 flashes per second) 1-28 h after a single oral dose of placebo on Day 1 and ICA-105665 on Day 2. A single blind design was used; investigators and sponsor, but not subjects, were aware of treatment assignment. Decreases in the photosensitivity range (defined as a reduction in the standard photosensitivity range of at least 3 frequency steps at three or more hourly measurements after dosing, compared to the time-matched assessments on Day 1) occurred in 1of 4 subjects at 100 mg, 2 of 4 subjects at 400 mg, and 4 of 6 subjects at 500 mg The single subject that received 600 mg experienced a serious TEAE (see below) before undergoing photic stimulation. One of the tested subjects had a significant reduction in photoparoxysmal responses after a 100 mg dose and a complete abolishment of response 2 h after a 400 mg dose. The duration of response appeared to increase with dose. One patient in the 400 mg cohort and 2 patients in the 500 mg cohort maintained partial suppression of photosensitivity for >20 h
Tolerability and adverse event profile
Three Phase I studies focused on safety and pharmacokinetic parameters demonstrated good tolerability and potential for b.i.d. dosing without titration. In these studies, healthy volunteers tolerated single doses up to 400 mg and multiple doses up to 600 mg/day for 7 days; subjects with epilepsy tolerated 400 mg/day in 2 divided doses for 7 days. There were no dose-limiting toxicities, severe or life-threatening TEAEs, serious TEAEs, or discontinuations due to TEAEs, nor were there important trends or changes from baseline for clinical laboratory, vital signs, ECG, or physical examination findings. The most common TEAE in subjects who received ICA-105665 was headache. Other commonly reported TEAEs were generally CNS-related, including dizziness and somnolence. Dizziness appeared to be the first TEAE related to treatment.
In the Phase II study in photosensitive epilepsy, single doses of ICA-105665 ranging from 100 to 400 mg were well tolerated. The 500 mg dose was associated with TEAEs (especially dizziness) in most subjects and was defined as the maximum tolerated dose. A single subject with juvenile myoclonic epilepsy and a history of generalized tonic-clonic seizures received a single 600 mg dose of ICA-105665 and experienced a brief tonic-clonic seizure, and the study was terminated. The patient recovered uneventfully and the role of ICA-105665 in the event was not clear.
Planned studies
With the acquisition of Icagen by Pfizer, Inc., ICA-105665 is now formally part of the Pfizer portfolio and future clinical studies are being planned by the new project team. Imepitoin (AWD 131-138 or ELB 138; 1-(4-chlorophenyl)-4-morpholino-imidazolin-2-one) is a new chemical entity that was previously presented at the EILAT IV and V conferences (Bialer et al., 1999 (Bialer et al., , 2001 . It was developed in the 1990s from a series of imidazolinones by Asta Medica and Arzneimittelwerk Dresden (AWD; later Elbion, Radebeul, Germany) (Rostock et al., 1998a) . Furthermore, it was tested in the NINDS-sponsored Anticonvulsant Screening Project (ASP). Imepitoin was selected for further development because of its broad spectrum of anticonvulsant activity, high therapeutic index, and its efficacy in tests predictive for anxiolytic effects. It underwent Phase I clinical studies, but further clinical development for humans was suspended. However, interesting findings in dogs (see below) led Boehringer Ingelheim (Germany) to the decision to develop imepitoin as a new AED for canine epilepsy.
Pharmacology Anticonvulsant activity in animal models
Imepitoin is active in primary screening tests for anticonvulsant activity in mice and rats using the maximal electroshock test (MES) and supramaximal stimulation with chemical convulsants such as pentylenetetrazol and bicuculline. Audiogenic clonic seizures in genetic models of epilepsy are potently inhibited, with ED 50 values of 2.6 mg/kg i.p. in DBA/2 mice and 5.0 mg/kg, i.p. in Frings mice. In addition, imepitoin elevates the chemically-induced seizure threshold in the i.v. pentylenetetrazol test in mice. It also increases the pentylenetetrazol-induced seizure threshold in dogs after single doses and after prolonged oral treatment with 5 or 40 mg/kg b.i.d. (Löscher et al., 2004) . In the MES threshold test in mice, imepitoin elevates the threshold for tonic hindlimb extension after i.p. and p.o. doses, starting at 30 and 50 mg/kg, respectively (Rostock et al., 1998a; Tober et al., 1998 Tober et al., , 1999 Bialer et al., 1999) . Imepitoin also exerts pronounced anticonvulsant effects in models for partial onset seizures. In fully amygdala-kindled rats, the threshold for induction of afterdischarges is increased dose dependently, with significant effects being already detectable at 1 mg/kg i.p., the lowest dose tested. Starting at 10 mg/kg i.p., imepitoin inhibits seizure severity after electrical stimulation at the elevated afterdischarge threshold current, whereas secondary generalization of the evoked kindled seizure is completely inhibited at 20 mg/kg i.p. Repeated treatment once daily with imepitoin during kindling acquisition delays significantly the development of generalized motor seizures at 20 and 30 mg/kg i.p. Imepitoin decreases the number and duration of spontaneous spikewave discharges in WAG rats, a model for absence epilepsy already at 3 mg/kg p.o., the lowest dose tested. After administration of 30 mg/kg p.o., spikes and waves are almost completely suppressed (98% inhibition of number and duration of discharges). In addition, imepitoin at a dose of 3 mg/kg p.o. inhibits the number and total duration of spikes and waves induced by i.p. administration of 25 mg/kg pentylentetrazol (Tober et al., 1999) . During repeated administration, no evidence of tolerance (i.e. no reduction of anticonvulsant activity) has been found in rodents and dogs, even when very high doses were given (Rostock et al., 1998b; Tober et al., 1998; Löscher et al., 2004) . In particular, during 29 days of oral treatment at 100 mg/kg in mice, no decrease in the effect on the MES threshold was observed. In further experiments in mice, activity in the MES test was not reduced after administration of 100 mg/kg i.p. b.i.d. for 5 days. In the MES test with supramaximal stimulation in rats, no change in anticonvulsant activity was seen after administration of 28 and 100 mg/kg p.o. for 5 days (Rostock et al., 1998b; Tober et al., 1998; Bialer et al., 1999) . In dogs, activity in the pentylenetetrazol seizure threshold test remained stable during treatment with 5 mg/kg or 40 mg/kg b.i.d. p.o. for 4 weeks (Löscher et al., 2004) .
Activity profile in models of anxiolytic activity
Starting at dosages of 3 mg/kg i.p. and p.o., imepitoin is active in mouse and rat models predictive of anxiolytic activity, such as innate fear and fear induced by open and high areas, light stimulation and unfamiliar animals (elevated maze, light-dark chamber, social interaction test). In punishment tests, anxiety was clearly decreased only in the Vogel conflict test in rats (Rostock et al., 1998b) .
Mechanism of action
Imepitoin acts as a low-affinity partial agonist at the benzodiazepine recognition site of the GABA A receptor (Rostock et al., 1998a; Sigel et al., 1998) . At 10 M, GABA currents are stimulated to 10-20% of the maximal stimulation achieved using diazepam. The threshold of stimulation is about 0.3-1.0 M. The GABA-potentiating, anxiolytic, and anticonvulsant effects of imepitoin could be counteracted by the benzodiazepine antagonist flumazenil, indicating that the interaction of imepitoin with the benzodiazepine site may be the main mechanism of action of this novel drug.
One major disadvantage of drugs acting via the benzodiazepine site of GABA receptors is their tolerance, dependence, and abuse liability. Partial agonists at this site have been suggested to offer advantages over full agonists in this regard (Löscher et al., 1990; Costa and Guidotti, 1996; Mehta and Ticku, 1999) . In line with this suggestion, imepitoin failed to produce benzodiazepine-like discriminative effects and drug self-administration behavior when tested in squirrel monkeys (Yasar et al., 2003) . Furthermore, no loss of anticonvulsant efficacy during prolonged treatment or withdrawal symptoms on termination of treatment were observed in mice or dogs (Löscher et al., 2004) .
In addition to its effects on GABA A receptors, imepitoin blocks voltage-activated Ca 2+ channels in a dose-dependent manner (Bialer et al., 1999) . A significant block is found at 1 M, and it is as yet unclear which channel subtype is affected. Imepitoin (1 and 100 M) also antagonizes the increased firing of action potentials induced by corticotrophin-releasing factor (CRF) in locus coeruleus neurons of murine brain stem slices. This effect could contribute to the anxiolytic activity. Imepitoin has no effects on the normal frequency of action potential firing in these neurons.
Toxicology
The TD 50 for motor impairment in the rotarod test is about 1000 mg/kg, p.o. in rats. This low neurotoxicity was confirmed in kindled rats with altered susceptibility to CNS adverse effects. The protective index, calculated as the ratio between the TD 50 in the rotarod test and the dose inducing anticonvulsant and anxiolytic activity (3 mg/kg), is 333 in rats after p.o. administration. Consistent with the low neurotoxicity, imepitoin showed no measurable effects on basal synaptic transmission in rat brain slices with orthodromically evoked population spikes (Dost, unpublished results).
Pharmacokinetics
Imepitoin is absorbed rapidly and extensively in rats and dogs, and shows a high metabolic stability when tested in vitro with human liver microsomes and human liver slices (Bialer et al., 1999) . Elimination half-lives in rats and dogs were dose-dependent, ranging from 1.1 to 6 h (Bialer et al., 1999; Löscher et al., 2004) .
Efficacy and tolerability in dogs with epilepsy
Epilepsy is the most common chronic neurological disease in dogs (about 0.6-1% of the dog population) Podell, 1996) . Currently, there is only one licensed AED for treatment of epileptic dogs, i.e., phenobarbital. Most other AEDs have too short half-lives in dogs . About 70-80% of all dogs with epilepsy are not controlled by phenobarbital, and treatment is associated with adverse effects and the risk of severe withdrawal seizures upon termination of treatment. Thus, new treatments for canine epilepsy are urgently needed. Based on the dose-finding experiments in a pentylentetrazol seizure model in dogs, b.i.d. oral dosing with imepitoin 10-30 mg/kg was used for first exploratory clinical trials in dogs with epilepsy (Löscher et al., 2004) . In a prospective trial in dogs with newly diagnosed epilepsy, monotherapy with imepitoin markedly reduced seizure frequency and severity without significant difference to standard treatments (phenobarbital or primidone), but was much better tolerated than the standard drugs. In dogs with chronic epilepsy, most dogs exhibited a reduction in seizure frequency and severity during add-on treatment with imepitoin (Löscher et al., 2004) .
Overall, the data in dogs demonstrate that the partial benzodiazepine receptor agonist imepitoin exerts significant anticonvulsant efficacy without tolerance in a dog seizure model as well as in epileptic dogs with spontaneously recurrent seizures. These data thus substantiate that partial agonism at the benzodiazepine site of GABA A receptors offers advantages versus full agonism and constitutes a valuable approach for treatment of seizures.
Based on these data, two large prospective and controlled multicenter trials were performed in epileptic dogs by Boehringer Ingelheim. 
Introduction and rationale for development
Galanin has been recognized as a potential anticonvulsant neuropeptide since the early work of Mazarati and coworkers (Mazarati et al., 1992; Mazarati et al., 1998 Mazarati et al., , 2000 . Galanin is one of several neuropeptides with demonstrated anticonvulsant activity (Robertson et al., 2010) . Galanin is presumed to exert its biological activity through the activation of galanin receptor (GalR) subtypes 1 and 2; both of which are widely expressed in the CNS (Lang and Kofler, 2011) . Early evidence demonstrating an the importance of both receptor types came from studies conducted in GalR1 knockout mice and in rats employing a GalR2 antisense approach (Mazarati et al. 2004a (Mazarati et al. ,b, 2006 Mazarati and Lu, 2005) .
The development of galanin as an AED has been hampered by its marginal metabolic stability and inability to penetrate the blood-brain-barrier when delivered systemically. Further, activation of peripheral GalR1 results in the inhibition of insulin release and subsequent hyperglycemia. Modification of the galanin backbone led to the identification of a series of metabolically stable, blood-brain-barrier penetrant novel galanin agonists that demonstrate anticonvulsant activity following systemic administration (Bulaj et al., 2008; Zhang et al., 2009 ). The first candidate galanin analog to be extensively evaluated was the GalR1-receptor preferring analog NAX 5055 . NAX 5055 was found to possess long-lasting and dose-dependent activity in the 6 Hz seizure model following i.v., i.p. s.c. and oral administration . NAX 5055 also exhibited potent efficacy in other models of epilepsy and pain. Unfortunately, NAX-5055 was subsequently shown to produce marked hyperglycemia that was associated with inhibition of insulin release. Subsequent investigations led to the discovery of NAX 810-2, a GalR2-preferring galanin agonist that displays similarly potent anticonvulsant activity in a battery of animal seizure and epilepsy models (Table 1) .
Pharmacology
Structure-activity relationship studies demonstrated that the N-terminal fragment GAL(1-16) retains potent agonist activity at hippocampal galanin receptors. Based on that knowledge, the following modifications were introduced to the GAL(1-16) analogs: (1) the Gly1 residue was replaced by sarcosine as N-methylation of Gly1 maintains nanomolar galanin receptor affinity, but with an ∼15-fold preference for GalR1 compared to GalR2. (2) ''atom shaving'' of this N-terminus substantially decreases GalR1 affinity while preserving relatively high GalR2 affinity (3) residues following critical Tyr9 were replaced by a combination of Lys residues and lipoamino acids, such as lysine-conjugated to long-chain carboxylic acids (Bulaj et al., 2008; Zhang et al., 2009; Robertson et al., 2010) .
For lead optimization studies, approximately 40 new analogs targeting GalR2 were chemically synthesized on a solid support using standard Fmoc protocols and an automated peptide synthesizer. The peptides were purified by reversed-phase HPLC separations and their identities were confirmed by mass spectrometry. The new series of analogs were screened for anti-seizure activity in the mouse 6 Hz 32 mA test following i.p. administration. NAX 810-2 is an initial lead analog from this series that has undergone extended pharmacologic characterization.
Anticonvulsant profile in experimental models
As shown in Table 1 , NAX 810-2 is potently active at both the 32 and 44 mA stimulation intensities in the mouse 6 Hz seizure model following i.p. administration and is effective in blocking sound-induced seizures in the Frings audiogenic seizure-susceptible mouse. NAX 810-2 is also potently active (Table 1) against the fully expressed seizure in the corneal kindled mouse model of partial epilepsy (Matagne and Klitgaard, 1998) . In contrast, it is inactive at substantially higher doses (i.e., 20 mg/kg, i.p.) in the maximal electroshock test. In this respect, NAX 810-2 displays an anticonvulsant profile similar to the GalR1 preferring analog NAX 5055. NAX 810-2 has been evaluated in the rotarod test for motor impairment. In this particular test, the median toxic dose was estimated to be greater than 32 mg/kg, i.p. yielding a wide protective index (PI = TD 50/ ED 50 ) of more than 10-fold for NAX 810-2 with the 6 Hz (32 mA) test.
As mentioned above, NAX 810-2 retains potent activity in the 6 Hz test even when the higher stimulation intensity (44 mA) is employed. The results obtained in the 6 Hz test are of particular interest because this model has evolved as a useful model for differentiating potential AEDs for treatment of refractory partial epilepsy (Barton et al., 2001 ). The overall prolife of NAX 810-2 in seizure models is unique compared to the majority of approved AEDs and most closely resembles that of levetiracetam. In addition to its anticonvulsant activity, the GalR1 preferring analog NAX 505-5 is effective in rodent models of acute and chronic pain . Similarly, NAX 810-2 following systemic administration is potently active in mouse models of inflammatory pain (Table 1) . It was active in the carrageenan assay and both the acute and chronic phases of formalin-induced pain in mice. The overall activity of NAX 810-2 supports the continued evaluation of these novel systemically active analogs targeting GalR2 for the treatment of epilepsy and pain.
Mechanisms of action
As described previously , the GalR1 preferring analog NAX 5055 displays low nanomolar binding affinity for both GalR1 and GalR2 with Ki values of 3.5 and 51 nM, respectively. In contrast, NAX 810-2 possesses low nanomolar binding affinity for GalR2 (Ki value 31.7 nM) compared to GalR1 (Ki value 494 nM). Importantly, the GalR1 binding affinity of NAX 810-2 is reduced >100-fold compared to the GalR1-preferring agonist NAX 505-5. Both NAX 5055 and NAX 810-2 are presumed to exert their antiepileptic effects through selective interaction with these G-protein coupled galanin receptors. Studies in rat brain slice preparations have shown that galanin inhibits glutamate release (Zini et al., 1993) . Further, activation of GalR2 has been shown to produce trophic effects in dorsal root ganglion neurons (Mahoney et al., 2003) and to be neuroprotective in hippocampal neurons (Elliott-Hunt et al., 2007) . Therefore, a mechanistically novel therapy targeting GalR2 may possess disease modifying properties though these neuroprotective and anti-inflammatory effects.
Planned studies
Ongoing studies will further define the efficacy and safety potential of NAX 810-2 and other leads from this new series targeting GalR2 for the treatment of pharmacoresistant POS. The preclinical development of a lead candidate targeting GalR2 is being advanced through IND filing supported by funding from a NINDS U01 translational research grant.
Introduction and rationale for development
Perampanel (E2007) is an orally active, non-competitive, and highly selective antagonist of the glutamate AMPA receptor (Hanada et al., 2011) . The AMPA receptor is a ligand-gated ion channel that has long been identified as a rational drug target for epilepsy. Excessive glutamate transmission is implicated in the initiation and spread of seizures, and as the AMPA receptor mediates the majority of fast synaptic transmission by glutamate it is theorized that an AMPA receptor antagonist will have anti-seizure activity (Rogawski and Loscher, 2004) .
Perampanel is the first AMPA receptor antagonist to be submitted for regulatory approval for any indication. It is supported by a large dataset, from Phase I studies, Phase II studies in patients with multiple sclerosis, Parkinson disease, neuropathic pain and epilepsy, and a large Phase III program in patients with POS. Through this program, over 4600 subjects have been exposed to perampanel in clinical trials (Eisai, Data on File).
Pharmacology
Studies reported by Hanada et al. (Hanada et al., 2011) have demonstrated that perampanel is a potent AMPA receptor antagonist, inhibiting AMPA-mediated Ca 2+ currents in vitro with an IC 50 of 93 nM. Perampanel has no effect on NMDAreceptor-mediated currents at this concentration; a small inhibition is seen at 300-times this concentration (Hanada et al., 2011) .
Further evidence of the selectivity of perampanel comes from ligand-binding studies, where perampanel, at a relatively high concentration of 10 M, did not inhibit by ≥50% the binding of ligands to 86 different cellular targets (Eisai, Data on file).
Perampanel is thought to act via a non-competitive (allosteric) mechanism, binding to a separate site on the AMPA receptor from the glutamate-binding site. Rather than directly competing with glutamate to inhibit its binding to the AMPA receptor, perampanel binds to an allosteric site and thereby prevents glutamate from opening the receptor. In support of this allosteric mechanism, radiolabeled perampanel is not displaced from rat forebrain membranes by glutamate or AMPA but is displaced by known noncompetitive AMPA receptor antagonists (Hanada et al., 2011) .
Anticonvulsant profile in experimental models
The anti-seizure effects of perampanel across a range of animal models were reported in the previous Eilat report and these data have now been published in full (Hanada et al., 2011) .
Other pharmacological properties AMPA receptors, when activated, drive the generation of excitatory post-synaptic potentials (EPSPs) to propagate action potentials through networks of neurons. It is interesting, therefore, to explore the effects of perampanel in neuronal networks. Perampanel inhibits AMPA-receptor mediated EPSPs in hippocampal slices with no effect on NMDA-or kainate-receptor-mediated EPSPs, demonstrating selectivity for AMPA-type glutamate receptors (Ceolin et al., 2012) Mechanism(s) of action Perampanel, as noted earlier, reduces the ability of glutamate to activate AMPA receptors via a non-competitive mechanism (Hanada et al., 2011) . The theoretical process by which this leads to clinical anti-seizure effects is by attenuating the neuronal hyperexcitability that characterizes epileptic brain regions. Glutamate is the predominant excitatory neurotransmitter in the brain, and AMPA receptors play a central role in seizure generation and spread (Rogawski and Loscher, 2004) . Currently approved AEDs predominantly act pre-synaptically to reduce neuronal excitability (e.g. Na + channel blockers, K + channel openers), reduce neurotransmitter release (e.g. Ca 2+ channel blockers, levetiracetam) or increase GABAergic inhibitory controls (benzodiazepines, tiagabine, vigabatrin). In contrast, perampanel acts post-synaptically to decrease excitability (Rogawski and Loscher, 2004) .
One theoretical consequence of the non-competitive mechanism of action is that the ability to inhibit AMPAreceptor activation should be maintained even when glutamate concentrations are high (as occurs during seizure activity). In contrast, a competitive antagonist would be out-competed and displaced from the glutamate-binding site when glutamate concentrations are high, and competitive antagonism is, therefore, surmountable (Kenakin, 2006) . The clinical implications of this are still being evaluated.
Toxicology
There have been no further toxicology studies since those reported in the previous report .
Pharmacokinetics
The pharmacokinetics of perampanel in healthy volunteers were described in the previous report . In summary, perampanel has a long half-life (∼70-110 h), is metabolized primarily by CYP3A4, and steady state is achieved in 14 days with once-daily dosing (Eisai, Data on File, . Recently presented population pharmacokinetic analyses support a one-compartment model and indicate slightly lower clearance in females than males .
Drug interactions
In a population pharmacokinetic analysis, using pooled data from the 3 Phase III clinical trials, perampanel had no effect on the clearance of other AEDs . Clearance of perampanel was increased 2-fold by oxcarbazepine and phenytoin and increased 3-fold by carbamazepine .
There is a positive relationship between plasma perampanel concentration and clinical response. As average exposure to perampanel at steady state increased, seizure frequency decreased and the probability of an individual being a responder (≥50% reduction in seizure frequency) increased significantly. Concomitant AEDs had no effect on the exposure/efficacy relationship for seizure frequency or the probability of response at any given plasma concentration .
Efficacy data
Data from perampanel Phase II trials were reported in the previous Eilat report and have now been published (Krauss et al., 2011) . Pharmacokinetic-pharmacodynamic (PK/PD) modeling from these Phase II trials established the no effect dose (2 mg/day), the minimum effective dose (4 mg/day), the mid effective dose (8 mg/day), and the high effective dose (12 mg/day).
Results from three Phase III trials in 1480 subjects have been presented (Study 304: French et al., 2012a; Study 305: French et al., 2012b and Study 306: Krauss et al., 2012) . These trials all utilized similar trial designs, with a 6-week baseline period, a 6-week titration period, and a 13-week maintenance period. Patients were ≥12 years of age, with refractory POS, and already taking 1-3 AEDs. Unless stated otherwise, data are reported over the entire 19-week double-blind treatment period (titration + maintenance).
The first study to be reported (306, NCT00700310) investigated perampanel at doses of 2, 4 and 8 mg/day and placebo. The median percent change from baseline in seizure frequency was significantly greater with 4 and 8 mg/day perampanel (−23.3%, p = 0.0026 and −30.8%, p < 0.0001, respectively) but not 2 mg/day (−13.6%) compared to placebo (−10.7%). The responder rate was significantly higher during the maintenance period in the groups randomized to 4 and 8 mg/day perampanel (28.5%, p = 0.0132 and 34.9%, p = 0.0003, respectively) but not 2 mg/day (20.6%) compared to placebo (17.9%) (Krauss et al., 2012) .
The next two studies confirmed the efficacy of the 8 mg/day dose and also included a higher dose (12 mg/day). Study 305 (NCT00699582) demonstrated a significant reduction in seizure frequency with perampanel 8 mg/day (median percent change from baseline: −30.5%, p < 0.001) and 12 mg/day (−17.6%, p = 0.011) versus placebo (−9.7%), and a significant increase in responder rate (33.3% at 8 mg/day, p = 0.0018 and 33.9% at 12 mg/day, p = 0.0006) versus placebo (14.7%) (French et al., 2012b) .
Study 304 (NCT00699972) also demonstrated a significant reduction in seizure frequency with perampanel 8 mg/day (median percent change from baseline: −26.3%, p = 0.0261) and 12 mg/day (−34.5%, p = 0.0158) versus placebo (−21.0%) but responder rates (37.6% and 36.1%, respectively) were not significantly greater than the high placebo responder rate (26.4%) (French et al., 2012a) . Placebo rates in study 304 were high, particularly in Central and South American study centers. Responder rates with perampanel were significantly higher than with placebo in the North American centers, but not the Central and South American centers. An explanation for this regional difference has not been forthcoming despite extensive analyses.
Tolerability and adverse event profile
Phase II studies showed that perampanel was tolerated at doses up to 12 mg/day (Krauss et al., 2011) , and Phase III studies revealed no additional safety concerns. In the first Phase III study (306), the most common TEAEs (occurring in ≥10% of patients from any treatment group) were dizziness (27% with 8 mg/day versus 10% with placebo), somnolence (16% versus 7%) and headache (11% versus 9%) (Krauss et al., 2010) . Serious TEAEs were not more frequent with study drug (3.6% with 8 mg/day) than with placebo (4.9%), and discontinuation rates due to TEAEs were low (7.1% with 8 mg/day versus 3.8% with placebo) (Krauss et al., 2012) .
In studies 304 (French et al., 2012a) and 305 (French et al., 2012b) , similar TEAEs were seen, and rates were generally higher with 12 mg/day than with 8 mg/day. In study 304, the most common TEAEs were dizziness (38.1% with 12 mg versus 9.9% with placebo), somnolence (17.2% versus 13.2%), irritability (14.2% versus 5.0%), headache (13.4% versus 13.2%), fall (12.7% versus 6.6%) and ataxia (11.9% versus 0%). Treatment discontinuations due to TEAEs were relatively low (placebo 5.8%, 8 mg/day 6.8%, 12 mg/day 17.9%) (French et al., 2012b) .
In study 305, most TEAEs were of mild or moderate severity, and severe TEAEs were reported in only 6.6%, 9.3% and 10.7% of patients in the placebo, perampanel 8 mg/day and 12 mg/day groups, respectively (French et al., 2012b) . The TEAEs that occurred in ≥10% of patients in any treatment group were dizziness (32.6% and 47.9% with perampanel 8 mg/day and 12 mg/day versus 7.4% for placebo), somnolence (12.4% and 18.2% versus 2.9%), fatigue (13.2% and 16.5% versus 8.1%), and headache (8.5% and 13.2% versus 13.2% with placebo) (French et al., 2012) . The incidence of TEAEs was lower during the maintenance period: dizziness (5.1% and 14.4% versus 4.8% with placebo), headache (6.8%, and 4.8% versus 4.0%) and fatigue (4.2% and 6.7% versus 2.4%) (Ryvlin et al., 2011) . The difference in TEAE rates between the titration period and the maintenance period might be explained by the somewhat rapid, forced titration paradigm of 2-mg increments each week over the 6 weeks of titration. Discontinuations due to TEAEs were higher in perampanel-treated patients compared with placebo (4.4%, 9.3%, and 19% with placebo, 8 mg, and 12 mg, respectively) (French et al., 2012b) . Rash led to discontinuation in 1.6% perampanel patients versus 0% in placebo patients. No abnormal trends in laboratory tests, including QTc, were observed (French et al., 2012b) .
The number and rates of rash were low in all three studies without evidence of a dose response (Study 304: placebo = 3 (2.5%), perampanel = 5 (1.9%); Study 305: placebo = 2 (1.5%), perampanel 8 (3.2%); Study 306: placebo = 2 (1.1%), perampanel 9 (1.7%). There were no reports of Stevens-Johnson syndrome.
Planned studies
In addition to the open-label extensions of the perampanel Phase II and Phase III studies, two other trials are underway. The first (NCT01393743) will explore the efficacy and safety of adjunctive perampanel in primary generalized tonic-clonic seizures and aims to enroll 165 subjects. The second (NCT01161524) will explore the effect of perampanel on cognition and growth and evaluate its safety, tolerability, and pharmacokinetics in adolescents with refractory POS.
Tonabersat
Upsher Smith Laboratories, Minneapolis, Minnesota, USA H. Steve White, PhD 1 and Paul Durham, PhD
Introduction and rationale for development
Tonabersat is one of a series of novel benzoylamino benzopyran compounds initially developed by SmithKline-Beecham for the treatment of migraine and epilepsy. The tonabersat binding site, primarily found in the brain, is distinct from that of other CNS pharmacologic agents, including antimigraine compounds, AEDs, amino acid analogues, and ion channel modulators. Tonabersat possesses a novel mechanism of action related to stereospecific activity at its binding site, which may be related to uncoupling of neuronal gap junctions. Further, this benzoylamino benzopyran class of compounds has been found to exhibit anti-seizure properties. The data described here detail the current studies evaluating the anti-seizure profile of tonabersat and its mechanism of action.
Pharmacology
In both mice and rats, standard in vivo and in vitro models were employed to establish the anti-seizure profile of tonabersat. These included, but were not limited to, models of generalized tonic-clonic seizures (MES, focal seizure with secondary generalization (6 Hz), POS with secondary generalization (hippocampal-kindled), and pharmacoresistant seizures with secondary generalization (lamotrigine-resistant kindled). Toxicity of tonabersat was assessed with the minimal motor impairment scale (MMI) or rotarod test, and minimal behavioral toxicity was subsequently quantitated (ED 50 and TD 50 ) at the time of peak anticonvulsant effect. Additionally, MES data were used to correlate tonabersat plasma exposure with anti-seizure activity and model a relationship between efficacy and tonabersat brain/plasma concentrations. The mechanism of action of tonabersat has been evaluated in an in vivo model of migraine. Briefly, Sprague-Dawley rats were injected with either tumor necrosis factor-␣ (TNF-␣), capsaicin, or both agents (TNF-␣ CAP) to stimulate trigeminal ganglion neurons to induce an inflammatory reaction. Cell-cell communication was investigated with True Blue dye-coupling under basal and inflammatory conditions in the presence and absence of tonabersat (10 mg/kg ip). Further, the effects of inflammation and tonabersat on the expression of connexins (Cx) in trigeminal ganglion neurons and glia were evaluated by quantitative RT-PCR and immunohistochemistry (Damodaram et al., 2009) (Garrett and Durham, 2008) . Across a number of preclinical studies, tonabersat demonstrated a definitive anti-seizure profile. Tonabersat demonstrated a dose-dependent inhibition of electrographic bursting in the in vitro K + hippocampal brain slice model, with an IC 50 = 0.5 m. While tonabersat was unable to reduce the frequency of bursting in entorhinal cortex/hippocampal brain slices, it did reduce individual burst duration by ∼26%. In vivo, tonabersat demonstrated low toxicity with a TD 50 > 250 mg/kg (mice) and >500 mg/kg (rats). Tonabersat significantly increased the threshold for electrically-induced tonic extension seizures. In this model, tonabersat displayed a long duration of action (e.g., up to 12 h). Further, tonabersat produced both time-and dose-dependent inhibition of tonic extension seizures in the rat MES model, which specifically correlated to tonabersat plasma and brain concentrations. While tonabersat was effective against audiogenic seizures (PI > 2000), it was not protective against 6 Hz (limbic) or clonic seizures induced by subcutaneous administration of picrotoxin or bicuculline. In addition, tonabersat did not inhibit fully expressed seizures in either hippocampal or lamotrigine-resistant kindled rats. While tonabersat exhibited anti-seizure activity similar to other AEDs, it exhibited a higher PI.
TNF-␣ or capsaicin alone did not increase True Blue dye movement. In contrast, when simultaneous injection of TNF-␣ and capsaicin did increase dye movement between neuronal and satellite glial cells of the trigeminal ganglion (Damodaram et al., 2009) . This finding provides evidence that activation of trigeminal ganglion neurons increase cellular communication between these cell types via gap junctions. RT-PCR and immunohistochemistry data demonstrate that Cx26, Cx36, and Cx40 are expressed in the trigeminal ganglions under basal conditions, (Damodaram et al., 2009, Garrett and Durham, 2008) and during inflammatory conditions the expression of these connexins is up-regulated. In the presence of tonabersat, the inflammatory-induced cellular communication between the neurons and satellite glia cells was abolished, and the increase in Cx26 expression was inhibited (Damodaram et al., 2009) . Interestingly, the inhibitory effects of tonabersat on Cx26 expression were specific, as tonabersat did not inhibit the up-regulation of Cx36 or Cx40.
Pharmacokinetics and drug interactions
Initial studies evaluating the clinical pharmacokinetics and drug interaction potential of tonabersat (2-80 mg) in both healthy individuals and migraineurs were summarized in a previous Eilat conference report .
Planned studies
Tonabersat is currently being evaluated in Phase I studies as an investigational drug for the treatment of epilepsy.
Valproic acid second generation derivatives
M. Bialer and B. Yagen Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel
Introduction
Since Eilat X (2010), significant progress has been made in the development of valnoctamide (VCD) as well as secbutyl-propylacetamide (SPD), a one-carbon homologue of VCD White et al., 2012) . VCD is a CNS-active chiral constitutional isomer of valpromide, the corresponding amide of valproic acid (VPA) that exhibits stereoselective pharmacokinetics in animals and humans (Bialer and Yagen, 2007; Bialer, 2012) . Both VCD and SPD possess two chiral centers in their chemical structure (denoted above with the asterisk *). VCD (racemate) was commercially available as an anxiolytic drug (Nirvanil ® ) in several European countries from 1964 until as recently as 2005 (Bialer and Yagen, 2007; Bialer, 2012) , and it is now being developed for the treatment of bipolar disorder. VCD also has displayed potential in epilepsy and neuropathic pain.
Pharmacology
Anticonvulsant activity profile in experimental models VCD (racemate and/or two of its individual enantiomers) demonstrated anticonvulsant activity in a wide array of anticonvulsant models in mice (MES, s.c. pentylentetrazol and 6 Hz psychomotor seizures) and rats (MES and s.c. pentylentetrazol) as described in the previous Eilat X Conference manuscript .
As summarized in Table 1 , SPD's anticonvulsant activity was defined in several rodent seizure and epilepsy models including: MES, 6 Hz psychomotor, s.c. pentylentetrazol, picrotoxin, bicuculline, audiogenic and corneal and hippocampal kindled seizures following i.p. administration (White et al., 2012) . SPD was also evaluated for its ability to block benzodiazepine-resistant status epilepticus induced by pilocarpine (rats) and soman (rats and guinea pigs) following i.p. administration. SPD was tested for its ability to block excitotoxic cell death induced by the glutamate agonists N-methyl-D-Aspartate (NMDA) and kainic acid (KA) using organotypic hippocampal slices and status epilepticus-induced hippocampal cell death using FluoroJade B staining. The cognitive function of SPD-treated rats that were protected against pilocarpine-induced convulsive status epilepticus was examined 10-14 days post SE using the Morris water maze.
SPD was highly effective and displayed a wide PI in the standardized seizure and epilepsy models employed (Table 1 ). SPD's wide PI values demonstrate that it is effective at doses well below those that produce behavioral impairment. Unlike VCD, SPD also displayed anticonvulsant activity in the rat lithium/pilocarpine model of status epilepticus. Thirty minutes after the induction of status epilepticus, the calculated rat ED 50 for SPD against convulsive status epilepticus in this model was 84 mg/kg. SPD was not neuroprotective in the in vitro organotypic hippocampal slice preparation; however, it did display hippocampal neuroprotection in both in vivo status epilepticus models (i.e., lithium/pilocarpine and soman) and treatment after the onset of lithium/pilocarpine-induced status epilepticus with SPD resulted in cognitive sparing in the Morris water maze, an effect that was associated with its marked antiseizure effect against pilocarpine-induced status epilepticus (White et al., 2012) .
When administered 20 and 40 min after status epilepticus onset, SPD (100-174 mg/kg) produced long-lasting efficacy (e.g., 4-8 h) against soman-induced convulsive and electrographic status epilepticus in both rats and guinea pigs. SPD-ED 50 values in guinea pigs were 67 mg/kg and 92 mg/kg when administered at the onset of, or 40 min after, status epilepticus onset, respectively.
Overall, the results obtained in two highly treatmentresistant models of status epilepticus demonstrate that SPD is a broad-spectrum anti-seizure compound that blocks status epilepticus induced by pilocarpine and soman and affords in vivo neuroprotection that is associated with cognitive sparing. SPD activity against status epilepticus is superior to diazepam in terms of rapid onset, potency and its effect on animal mortality and functional improvement.
Other pharmacological properties: Reversal of tactile allodynia
The antiallodynic activity of VCD and two of its individual stereoisomers (2R,3S)-VCD and (2S,3S)-VCD in the spinal nerve ligation (or Chung) model for neuropathic pain in rats was described in the Eilat X Conference manuscript ). SPD's ED 50 value in the spinal nerve ligation model of 49 mg/kg was very similar to that of VCD (ED 50 = 52 mg/kg) (Kaufmann et al., 2009 (Kaufmann et al., ,2010 .
Teratogenicity
The lack of notable teratogenicity of VCD and (2R,3S)-VCD and (2S,3S)-VCD in SWV/Fnn mice which are highly susceptible to VPA-induced teratogenicity was previously described (Bialer and Yagen, 2007; . Following a successful Phase IIa study in patients with mania funded by the Stanley Medical Research Institute (SMRI) (Bersudsky et al., 2010) , the SMRI had a pre-IND meeting with the FDA-Division of Psychiatry Products. As requested by the FDA, the SMRI in collaboration with Yissum (Hebrew University Technology Transfer Company and VCD patents' owner) conducted teratogenicity studies comparing VCD to VPA (head-to-head) in mice, rats and rabbits at Covance Laboratories. In these additional studies, VCD in contrast to VPA failed to demonstrate teratogenic potential in mice and rabbits. In rats a modest teratogenic signal was observed at plasma concentrations 15-times higher than VCD therapeutic plasma levels.
A follow-up dose-response study with high doses of VCD and VPA in SWV/Fnn mice is currently in progress in the laboratory of Prof. Richard H. Finnell at the University of Texas in Austin, TX, USA. The study objective is to perform a comparative evaluation of VCD and VPA. Outcome measures of this study include assessment of: (a) neural tube defect response rates, and (b) soft tissue and skeletal integrity. Embryos will also be collected at critical times during development for genetic microarray studies to compare the impact on gene expression between a known teratogen, VPA, with VCD to see how they impact critical genetic pathways that regulate normal development.
Pharmacokinetics in experimental animals
The results of a previously conducted stereoselective pharmacokinetic analysis of VCD were summarized in the Eilat X Conference manuscript .
SPD pharmacokinetics was also studied following i.p. administration 60 mg/kg to naïve male Sprague-Dawley rats. SPD was found to have a clearance of 0.3 L/h that was mainly metabolic, as only 0.1% of the SPD dose was excreted unchanged in the urine. In rats, SPD displayed a 7-fold higher clearance than VCD due to its higher lipophilicity. SPD volume of distribution was 3-times greater than that of VCD (White et al., 2012) . As a consequence of these opposite trends in clearance and volume of distribution, SPD half-life was similar to that of VCD.
The relationship between the pharmacokinetic profile of SPD and its efficacy against soman-induced status epilepticus (PK-PD relationship) was evaluated. SPD (60 mg/kg, i.p.) was administered 20 min after the onset of status epilepticus. A PK-PD correlation (assuming linear pharmacokinetics) showed that SPD effective plasma levels in the soman-induced status epilepticus model ranged between 8-40 mg/L (20 min post seizure onset) and 12-50 mg/L (40 min post seizure onset). The time to peak effect (PD-t max ) occurred after the time of peak plasma levels (PK-t max ). This lag time may indicate a slow distribution of SPD to the extra-plasmatic active site responsible for SPD's anticonvulsant activity. This slower distribution to the active site may contribute to the fact that SPD's effect (responder rate) declined at a significantly slower rate than SPD plasma levels and in a few rats lasted for 24 hours when SPD was administered 20 min post status onset.
Clinical data
Recently, a successful double-blind controlled Phase IIa clinical trial funded by the SMRI with VCD racemate in patients with mania was completed (Bersudsky et al., 2010; . This study showed that VCD could be an important substitute to VPA in women of child-bearing age with bipolar disorder.It is worth emphasizing that based on head-to-head comparison with VPA in mice, rats and rabbits (unpublished data on file) VCD is the first potential effective mood stabilizer without significant teratogenicity in animal models.
Ongoing and planned studies
Although VPA is the most prescribed AED, its clinical use is restricted in women of child-bearing age and in children due to its teratogenicity and hepatotoxicity, respectively (Bialer and Yagen, 2007) . The development of VCD and its introduction as a new and potentially non-teratogenic/nonhepatotoxic CNS agent that is more potent than VPA, may offer a safer alternative for the treatment of patients with bipolar disorder, epilepsy and neuropathic pain . Following the successful Phase IIa clinical trial, VCD is currently undergoing a 3-week SMRI-funded Phase IIb, randomized double-blind multicenter study in 300 patients with bipolar manic episodes. The study is a 3-arm monotherapy parallel group trial in which patients are randomized to placebo (n = 120), VCD 1500 mg/day (n = 120) and risperidone, up to 6 mg/day (n = 60). The study's major objective is to evaluate the efficacy of VCD compared to placebo in patients with acute manic or mixed episodes. Risperidone is included as an active control to ascertain the trial's assay validity. 
VX-765

Introduction and rationale for development
Although many treatments are available in the United States, there are approximately 800,000 patients with epilepsy that continue to have seizures despite treatment with 2 or more antiepileptic drugs (AEDs). Thus, there may be important components underlying the disease that are not being addressed by current therapies. There is increasing evidence that inflammation plays an important role in establishing and maintaining seizures (Perucca et al., 2007) . Surgical specimens obtained from human brains of patients with treatment-resistant epilepsy show a number of inflammatory features, including elevated levels of interleukin converting enzyme (ICE, also known as caspase-1) and interleukin 1␤ (IL-1␤) and an increase in IL-1␤ receptors Vezzani et al., 2008) . These human brain studies suggest that ICE/IL-1␤ may be involved in causing epilepsy, particularly epilepsy that is resistant to current treatments. Several nonclinical experiments support an important role for ICE/IL-1␤ systems in epilepsy and indicate that inhibition of ICE/IL-1␤ has therapeutic potential for treating epilepsy .
Pharmacology
VX-765 (developed by Vertex Pharmaceuticals Incorporated) is a selective and reversible inhibitor of interleukinconverting enzyme (ICE; srtucture above) (Wannamaker et al., 2007) . VX-765 is currently in Phase 2 development.
Phase IIa study
A 6 week phase IIa randomized, double-blind, multicenter, placebo-controlled study was completed in subjects (18-64 years old) with treatment-resistant partial epilepsy receiving 1-4 concomitant AEDs. Treatment resistance was defined as failure to achieve seizure control despite adequate trials of 2 different AEDs. Subjects were randomized 4:1 to VX-765 900 mg tid, (n = 48) or placebo (n = 12). Subjects had to have at least 6 observable partial onset seizures (POS) during the 6 weeks between screening and the start of the treatment period (the ''baseline period''), and at least one seizure in 3 of the 6 weeks. The 6-week treatment period was followed by a 6-week observation period off study drug. The primary endpoint was safety and tolerability. Secondary endpoints included percent reduction in seizure frequency during the 6 week treatment period relative to the baseline period, percent of subjects with ≥50% reduction in seizure frequency (''responder-rate'') during the 6 week treatment period relative to the baseline period, and percent of subjects that become seizure-free during the last 2 weeks of the treatment period.
Safety and tolerability
A total of 35 subjects (72.9%) in the VX-765 group had at least 1 TEAE during the 6 week treatment period compared with 10 subjects (83.3%) in the placebo group. The most common TEAE was dizziness (16.7%). One subject in the VX-765 group had a rash that led to early discontinuation from treatment. Serious TEAE occurred in 6.3% (3/48) of VX-765 subjects (hernia surgery, pain, and acute worsening of complex partial seizures post-treatment) and 0% (0/12) of placebo subjects. All three serious TEAEs were determined by the need for hospitalization.
Efficacy results
A summary of the secondary efficacy assessments are shown in Table 4 . The mean percent reduction in seizure rates were 15.6% in the VX-765 group and 7.0% in the placebo group. There was a ≥50% reduction in seizures in 18.8% of subjects in the VX-765 group versus 8.3% in the placebo group. The differences in reduction in seizure rate and 50% responder rates did not meet statistical significance between the two groups. Overall, 12.5% of the VX-765 subjects were seizure free during the last 2 weeks of treatment versus 0% in the placebo group. Because animal data suggested a possible delayed effect of VX-765, a post hoc analysis was performed to determine whether stronger effects might be seen later in the treatment period. We evaluated a 4-week ''hybrid'' period consisting of the final 2 weeks of treatment plus the 2 week post-treatment (follow-up) period (Tables 5 and 6 ). During the hybrid period, there appeared to be a trend towards a better 50% responder rate in the VX-765 subjects (31.3% in the VX-765 group compared with 8.3% in the placebo group). These post hoc analyses suggest that there may be a delayed beneficial effect of VX-765 that persists for some time after drug is discontinued. Future studies can further evaluate these early observations.
Ongoing clinical studies
A double-blind, placebo-controlled, multicenter, international study in treatment resistant POS has been initiated . This study is a 13-week dose-ranging study of VX-765, as adjunctive treatment, to evaluate the efficacy and safety in subjects with treatment-resistant partial onset seizures. However, on September 25, 2012, Vertex a Hybrid = last 2 weeks of treatment plus first 2 weeks of follow up. The hybrid period was 4 weeks relative to the 6 weeks of the baseline period. made a business-related decision to stop enrollment in this study. Approximately 40 subjects were advancing through the 8-week baseline period and almost 20 subjects had been randomized into the treatment phase of the study. Subjects will be permitted to stay in the study for its full planned duration. Though substantially underpowered for rigorous statistical analyses; data will be analyzed and thoroughly examined for safety assessments and potential effectiveness of treatment. 
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YKP3089
Introduction
YKP3089 is a novel tetrazole derived compound with one chiral center (denoted above with an asterisk). It is active in a broad range of animal models of epilepsy. It is currently in Phase II clinical development at SK Life Science.
Pharmacology
Anticonvulsant profile in experimental models YKP3089 displays a broad-spectrum of anticonvulsant activity in rodent seizure and epilepsy models (Tables 1 and 2 ). It has been previously reported to prevent minimal electroshock-induced seizures in both mice and rats, with ED 50 values of 9.8 mg/kg, i.p. and 1.9 mg/kg, p.o., respectively. In mice, YKP-3089 prevents minimal clonic seizures induced by subcutaneously administered pentylentetrazol and picrotoxin with ED 50 's of 28.5 and 34.5 mg/kg, i.p., respectively. YKP3089 was also effective against pentylentetrazol-induced clonic seizures and lithium/pilocarpine-induced status epilepticus in rats following i.p. administration (ED 50 : 14 and 7 mg/kg, i.p., respectively). YKP3089 was found to be effective in two models of POS, i.e., the hippocampal kindled rat (ED 50 = 16.4 mg/kg, i.p.) and the mouse 6 Hz psychomotor seizure model (Tables 1 and 2 ). It is worth noting that little change in the potency of YKP3089 was observed in the 6 Hz test when the current was increased from 22 to 32, to 44 mA, with ED 50 s of 11, 18 and 17 mg/kg, i.p. respectively.
Other pharmacological properties
As described previously, YKP3089 shows activity in mouse and rat models of anxiety and is more efficacious than gabapentin in the spinal nerve ligation (Bennett and Chung) model of neuropathic pain . YKP3089 displays neuroprotective activity in the hypoxia-induced lethality mouse model.
Toxicology
YKP3089 was negative in all genotoxicity assays tested (Ames bacterial reverse mutation, mouse lymphoma and in vivo rat bone marrow micronucleus studies). No evidence of teratogenicity was observed in reproductive studies in rats and rabbits. YKP3089 did not affect cardiovascular functions in a telemetry cardiovascular study in monkeys.
Clinical pharmacokinetics
Following single oral administration, plasma YKP3089 levels were dose-proportional. In single dose studies, YKP3089 pharmacokinetic parameters were linear over a large dose range (5-750 mg), with a median time of peak concentration of 1.5-3.5 hours, a mean volume of distribution (Vd/F) of 37-55 L, a half-life of 30-75 h and a mean oral clearance (CL/F) of 0.63 L/h. In a multiple-dose 14-day study with once-daily dosing, both C max and AUC correlated linearly with the dose over the range of 50 mg/day to 300 mg/day. There was no significant effect of food (high-fat diet) on YKP3089 pharmacokinetics.
Tolerability and adverse events profile
In Phase I healthy volunteer studies, YKP3089 was welltolerated after single oral doses ranging from 5 mg to 750 mg In multiple ascending oral dose studies in healthy volunteers of 14-17 days duration, doses ranging from 50 mg/day to 200 mg/day were well tolerated. Doses of 250-300 mg/day were associated with a higher incidence of CNS-related TEAEs.They were mild to moderate in intensity and resolved rapidly. No clinically significant changes in ECGs or laboratory parameters were observed.
Ongoing Phase II study
A Phase II, multicenter, double-blind, randomized, placebo controlled trial to evaluate the efficacy and safety of adjunctive YKP3089 in subjects with treatment-resistant POS (NCT01397968) is ongoing. Disclosure M. Bialer has received in the last two years speakers or consultancy fees from Bial, BioAvenir, CTS Chemicals, Desitin, Medgenics, Rekah, Sepracor, Tombotech, UCB Pharma and Upsher Smith. He has been involved in the design and development of new antiepileptics and CNS drugs as well as new formulations of existing drugs.
S. I. Johannessen has served in the alst two years as a paid consultant to Bial.
R. H. Levy has been a consultant in the last year for the Metabolism and Transport Drug Interaction Database at the University of Washington and for Biocodex.E. Perucca
